Company profile for Eledon Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are focused, we are agile, we are driven, we do not cut corners, and we are guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) antibodies for patients in need of a potentially life-saving treatment. With AT-1501 as the cornerstone of our pipeline, Eledon is poised to leverage our expertise in both anti-CD40 Ligand biology and drug development to advan...
We are focused, we are agile, we are driven, we do not cut corners, and we are guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) antibodies for patients in need of a potentially life-saving treatment. With AT-1501 as the cornerstone of our pipeline, Eledon is poised to leverage our expertise in both anti-CD40 Ligand biology and drug development to advance therapies seeking to help patients undergoing organ or cellular transplantation, as well as those living with autoimmune or neurodegenerative diseases, all of whom face limited options.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
19900 MacArthur Blvd., Suite 550 Irvine, California 92612
Telephone
Telephone
+1 949-238-8090
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196846/0/en/Eledon-Pharmaceuticals-to-Participate-in-the-37th-Annual-Piper-Sandler-Healthcare-Conference.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/18/3190482/0/en/Eledon-Reports-Preliminary-Data-from-First-Six-Patients-with-Type-1-Diabetes-Treated-with-Tegoprubart-as-the-Core-Immunosuppressant-Following-Islet-Transplantation-in-Investigator-.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188645/0/en/Eledon-Pharmaceuticals-Announces-Recent-Business-Highlights-and-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186141/0/en/Eledon-Pharmaceuticals-Announces-Pricing-of-50-Million-Underwritten-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/11/3185833/0/en/Eledon-Pharmaceuticals-Announces-Proposed-Underwritten-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

GLOBENEWSWIRE
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3183316/0/en/Eledon-Presents-Phase-2-BESTOW-Trial-Results-for-Tegoprubart-for-the-Prevention-of-Rejection-in-Kidney-Transplantation-at-the-American-Society-of-Nephrology-s-Kidney-Week-2025-Annu.html

GLOBENEWSWIRE
06 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty